An interventional study of CSF sample in Nosocomial Infection, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Cross Infection with a site in France — 8 open to participants now, 9 under way, 1 of them phase 3. Cross Infection · France.
Among the 47 studies in Cross Infection with a site in France, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 41st registered.
287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.
Browse Cross Infection studies →8 of the 47 studies in Cross Infection with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+ · Healthy volunteers
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 27 Cross Infection studies recruiting now, 23 (85%) set no upper age limit and 2 (7%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 185 is close to the median of 193 across 170 interventional studies indexed under Cross Infection.
Median enrollment 244 across the 23 interventional studies, 496 across the 24 observational. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 47 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 1 study filed under Cross Infection — fewer than ten, so there is no comparison to draw.
4 of the studies in Cross Infection with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT06482463University Hospital, ToulouseDiagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis | 2027-02 |
| NCT06643039Hospices Civils de LyonNosocomial Respiratory Virus Infection | 2027-07-05 |
| NCT07822971Centre Hospitalier Régional Metz-ThionvilleImpact of an On-site Simulation-based Training Programme on Adherence to Standard Precautions and Healthcare-associated Infections in Adult Intensive Care | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Cross Infection with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TOTEM study is a single-center study designed to evaluate the performance of the D-lactate assay in cerebrospinal fluid (CSF) for the diagnosis of ventriculostomy-related nosocomial meningitis. The study will be conducted in the neurosurgical intensive care unit of the Toulouse University Hospital, in patients with a suspected diagnosis of ventriculostomy-related nosocomial meningitis.
For each study participant, an additional CSF sample will be taken from the ventriculostomy during the routine sampling performed for the diagnosis of nosocomial meningitis. This sample will be stored at -80°C. Assays of D-lactate, procalcitonin (PCT), and pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNFa) will be performed serially on these CSF samples.
If the CSF sample taken at inclusion does not meet the criteria for nosocomial meningitis, a second sample will be taken 48 to 96 hours later to reassess the cellularity of the CSF. Finally, the end-of-participation visit takes place after 4 weeks. Two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Finally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
Biological: CSF sample
Finally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
Biological: CSF sample
an additional CSF sample of 1 ml is taken from the external ventriculostomy
Comparison of Sensitivity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis
Calculation of the sensitivity obtained for the determination of CSF D-lactate in patients with suspected ventriculostomy-related nosocomial meningitis. Thes parameter will be compared with those obtained for the usual biological markers.
Time frame: Day 0
Comparison of Specificity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis
Calculation of the specificity obtained for the determination of CSF D-lactate in patients with suspected ventriculostomy-related nosocomial meningitis. Thes parameter will be compared with those obtained for the usual biological markers.
Time frame: Day 0
sensitivity Parameter of Combined D-Lactate and Pro-Inflammatory Cytokines in CSF
sensitivity parameter calculated for the combined assay of D-lactate and pro-inflammatory cytokines in CSF.
Time frame: Day 0
specificity Parameter of Combined D-Lactate and Pro-Inflammatory Cytokines in CSF
specificity parameter calculated for the combined assay of D-lactate and pro-inflammatory cytokines in CSF.
Time frame: Day 0
Sensitivity Parameter of Combined D-Lactate and and cyto-biochemical parameters in CSF.
sensitivity parameter calculated for the combined assay of D-lactate and routinely assayed cyto-biochemical parameters (L-lactate, proteins, glucose, cellularity) in CSF.
Time frame: Day 0
specificity Parameter of D-lactate and cyto-biochemical parameters in CSF.
specificity parameter calculated for the combined assay of D-lactate and routinely assayed cyto-biochemical parameters (L-lactate, proteins, glucose, cellularity) in CSF.
Time frame: Day 0
Sensitivity Parameter of D-lactate in CSF depending on the nature of the bacterial species identified.
Sensitivity Parameter calculated for the D-lactate assay in CSF according to the nature of the bacterial species identified.
Time frame: Day 0
specificity Parameter of D-lactate in CSF depending on the nature of the bacterial species identified.
specificity Parameter calculated for the D-lactate assay in CSF according to the nature of the bacterial species identified.
Time frame: Day 0
Sensitivity Parameter of D-lactate in CSF according to the presence or absence of antibiotic therapy before collection.
Sensitivity Parameter calculated for the determination of D-lactate in CSF according to the presence or absence of antibiotic therapy prior to sampling.
Time frame: Day 0
specificity Parameter of D-lactate in CSF according to the presence or absence of antibiotic therapy before collection.
specificity Parameter calculated for the determination of D-lactate in CSF according to the presence or absence of antibiotic therapy prior to sampling.
Time frame: Day 0
Sensitivity Parameter for the determination of CSF D-lactate in culture-negative bacterial meningitis.
Densitivity Parameter calculated for the determination of D-lactate in CSF in culture-negative bacterial meningitis.
Time frame: Day 0
specificity Parameter for the determination of CSF D-lactate in culture-negative bacterial meningitis.
specificity Parameter calculated for the determination of D-lactate in CSF in culture-negative bacterial meningitis.
Time frame: Day 0
Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.
Of 59 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 24 months is above that.
Counting every sponsor, half of 61 studies reached it within 16 months; a quarter within 7 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →